A ONCE-WEEKLY GLP-1 RA

A ONCE-WEEKLY GLP-1 RA

Ozempic® is now covered by ALL public formularies across Canada!

map-canada Created with Sketch.

Select a province/territory or formulary body to find out additional details about public coverage.

Ozempic® is also covered by most private formularies across Canada.

Alberta Drug Benefit List (ADBL)

Special authorization: As add-on therapy for the treatment of type 2 diabetes in patients with intolerance to and/or inadequate glycemic control on: a sufficient trial (i.e., a minimum of 6 months) of metformin, AND a sulfonylurea, AND for whom insulin is not an option; OR for whom these products are contraindicated. Special authorization may be granted for 24 months.6

BC Fair PharmaCare

Special authority: As part of treatment for type 2 diabetes mellitus after inadequate glycemic control on maximum tolerated doses of dual therapy of metformin and a sulfonylurea or dual therapy of metformin and an insulin.
Special notes: Coverage will be provided for either semaglutide or an eligible dipeptidyl peptidase-4 (DPP-4) inhibitor; for patients that have coverage for DPP-4 inhibitor, approval for semaglutide coverage will result in discontinuation of coverage for DPP-4 inhibitor; patients intolerant to a sulfonylurea may be considered for coverage. Patients intolerant to glyburide may try another sulfonylurea (e.g., gliclazide, which is available through the PharmaCare Special Authority program).7

Manitoba Pharmacare

Exception drug status: For the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control.8

New Brunswick (NBPDP)

Special authorization: For the treatment of type 2 diabetes mellitus as a second drug added to metformin for patients who have inadequate glycemic control on metformin; or third drug added to metformin and a sulfonylurea for patients who have inadequate glycemic control on metformin and a sulfonylurea. Clinical note: For patients who cannot take metformin due to contraindications or intolerances, details must be provided.9

Non-Insured Health Benefits (NIHB)

Open benefit with a therapeutic note: For the treatment of type 2 diabetes in combination with metformin alone, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.10

Newfoundland and Labrador (NLPDP)

Special authorization: For the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control.11

Nova Scotia Pharmacare

Exception status: For the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control.12

Northwest Territories (EHB)

Open benefit with a therapeutic note: For the treatment of type 2 diabetes in combination with metformin alone, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.10,13

Nunavut (EHB)

Open benefit with a therapeutic note: For the treatment of type 2 diabetes in combination with metformin alone, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.10,14

Ontario Drug Benefit (ODB)

General benefit with a therapeutic note: For the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control.15

PEI Pharmacare

Special authorization: For the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control.16

Quebec (RAMQ)

Exceptional medication: For the treatment of type-2 diabetic persons, in association with metformin, where a sulfonylurea is contraindicated, not tolerated, or ineffective. Authorization is given for a weekly maximum dose of 1 mg. Ineffectiveness means the non-attainment of the value of glycated hemoglobin (HbA1c) adapted to the patient.17

Saskatchewan Drug Plan

Exception drug status: For the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control.18

Veterans Affairs Canada (PDP)

Open benefit: Standard benefit available Canada-wide for eligible clients.19

Yukon Territory (PHRM and CHRN)

Exceptional drug status: In addition to metformin and a sulfonylurea for patients with inadequate glycemic control on metformin and a sulfonylurea.20

AB, Alberta; BC, British Columbia; CHRN, Chronic Disease Program; EHB, extended health benefit; MB, Manitoba; NB, New Brunswick; NIHB, Non-Insured Health Benefits; NL, Newfoundland and Labrador; NS, Nova Scotia; NT, Northwest Territories; NU, Nunavut; ON, Ontario; PE, Prince Edward Island; PDP, prescription drug program; PHRM, pharmacare; QC, Quebec; RAMQ, Régie de l'assurance maladie du Québec; SK, Saskatchewan; VAC, Veterans Affairs Canada; YT, Yukon.

Contact us

Novo Nordisk would like every healthcare practitioner to be able to obtain information as easily and quickly as possible.
If you need information about Ozempic®, please contact:

Novo Nordisk Canada Inc.
101-2476 Argentia Road
Mississauga, Ontario
L5N 6M1

Business hours are:
Monday to Friday from
8:30 a.m. to 5:00 p.m. EST

Main number:
905-629-4222
Toll-free:
1-800-465-4334

Main fax number:
905-629-8662
Toll-free fax number:
1-844-465-2225